ASH 2023 | R-GemOx plus nivolumab versus R-GemOx as second-line therapy for LBCL
Gerhard Held, MD, Westpfalz-Klinikum, Kaiserslautern, Germany, discusses an interim analysis of the NIVEAU trial (NCT03366272) comparing rituximab, gemcitabine and oxaliplatin (R-GemOx), a common immuno-chemotherapy regimen, to R-GemOx plus nivolumab as second-line therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Although the study revealed no significant difference in progression-free survival (PFS) between the two treatment arms, there was a noticeable trend toward improved overall survival (OS) in patients treated with nivolumab, suggesting its potential to enhance the efficacy of subsequent therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol-Myers Squibb, Janssen, MSD, Abbvie, Amgen; Honoraria: Bristol-Myers Squibb, Janssen, MSD, Abbvie, Amgen; Research Funding: Bristol-Myers Squibb
